A plus AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation

被引：0

作者：

Heyman, Benjamin ^{[1
]}

Choi, Michael ^{[2
]}

Kipps, Thomas J. ^{[3
]}

机构：

[1] UC San Diego Moores Canc Ctr, Dept Med, Div Regenerat Med, UC San Diego, La Jolla, CA 92093 USA

[2] Dept Med, Div Hematol Oncol, UC San Diego, La Jolla, CA 92093 USA

[3] Ctr Novel Therapeut, Dept Med, Div Hematol Oncol, UC San Diego, La Jolla, CA 92093 USA

来源：

CASE REPORTS IN HEMATOLOGY | 2024年 / 2024卷

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; BRENTUXIMAB VEDOTIN; PHASE-II; CHEMOTHERAPY; VENETOCLAX; OUTCOMES; THERAPY; DISEASE; ABVD; MOPP;

D O I：

10.1155/2024/7612622

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hodgkin lymphoma variant of Richter's transformation (HvRT) is a rare complication for patients with chronic lymphocytic leukemia (CLL), with an overall poor prognosis. We present the first known case series of patients with HvRT treated with the combination of brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A + AVD). In our series of 4 patients, two patients treated with A + AVD for HvRT had durable remissions of 40 and 42 months, while two patients had disease progression and ultimately died. Continued investigation into the optimal management for patients with HvRT is still needed.

引用

页数：8

共 50 条

[1] Hodgkin's Lymphoma Variant of Richter's Syndrome
Vasilj, Ankica
Kojic-Katovic, Sandra
Maricevic, Ivana
Zokvic, Edita
Kelcec, Iva Bobus
Tomas, Davor
Curic-Juric, Silva
COLLEGIUM ANTROPOLOGICUM, 2010, 34 (01) : 295 - 299
[2] Nivolumab plus AVD in Advanced-Stage Classic Hodgkin's Lymphoma
Herrera, A. F.
LeBlanc, M.
Castellino, S. M.
Li, H.
Rutherford, S. C.
Evens, A. M.
Davison, K.
Punnett, A.
Parsons, S. K.
Ahmed, S.
Casulo, C.
Bartlett, N. L.
Tuscano, J. M.
Mei, M. G.
Hess, B. T.
Jacobs, R.
Saeed, H.
Torka, P.
Hu, B.
Moskowitz, C.
Kaur, S.
Goyal, G.
Forlenza, C.
Doan, A.
Lamble, A.
Kumar, P.
Chowdhury, S.
Brinker, B.
Sharma, N.
Singh, A.
Blum, K. A.
Perry, A. M.
Kovach, A.
Hodgson, D.
Constine, L. S.
Shields, L. K.
Prica, A.
Dillon, H.
Little, R. F.
Shipp, M. A.
Crump, M.
Kahl, B.
Leonard, J. P.
Smith, S. M.
Song, J. Y.
Kelly, K. M.
Friedberg, J. W.
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (15) : 1379 - 1389
[3] Hodgkin's Lymphoma as a Unique Variant of Richter Syndrome
Sarid, Nadav
Perry, Chava
Mittelman, Moshe
ISRAEL MEDICAL ASSOCIATION JOURNAL, 2013, 15 (10): : 646 - 647
[4] Hodgkin’s lymphoma as Richter’s transformation in chronic lymphocytic leukemia
Alberto Fabbri
Emanuele Cencini
Monica Bocchia
Medical Oncology, 2014, 31
[5] Hodgkin's lymphoma as Richter's transformation in chronic lymphocytic leukemia
Fabbri, Alberto
Cencini, Emanuele
Bocchia, Monica
MEDICAL ONCOLOGY, 2014, 31 (04)
[6] Hodgkin's disease variant of Richter's transformation -: A case report
Isikdogan, A
Ayyildiz, O
Büyükbayram, H
Müftüoglu, E
MEDICAL ONCOLOGY, 2002, 19 (02) : 109 - 112
[7] Hodgkin's variant of richter's transformation: Is transplant always an answer?
Vanidassane, Ilavarasi
Gogia, Ajay
Sharma, Vinod
Mallick, Soumya
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (02) : 307 - 308
[8] Transformation from chronic lymphocytic leukemia to classical Hodgkin lymphoma: an unusual Richter syndrome variant
Li, Kaimin
Liu, Jing
Li, Weilong
Zhou, Qin
Jiang, Lei
Chu, Xiaoxia
Pan, Xubo
Qu, Guimei
Xu, Junqing
Yu, Guohua
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (11): : 12703 - +
[9] A plus AVD versus eBEACOPP in advanced-stage Hodgkin lymphoma
Diehl, Louis F.
LANCET HAEMATOLOGY, 2021, 8 (06): : E384 - E386
[10] Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy
Taneja, Alankrita
Jones, Jade
Pittaluga, Stefania
Maric, Irina
Farooqui, Mohammed
Ahn, Inhye E.
Wiestner, Adrian
Sun, Clare
LEUKEMIA & LYMPHOMA, 2019, 60 (02) : 519 - 522

← 1 2 3 4 5 →